Medtronic's Operational Offensive Hits High Gear, but the Stock Stays in a Holding Pattern
Published on 06/18/2026 at 16:57 | Redaktion boerse-global.de
Medtronic has been stacking up positive developments — a fresh acquisition, a new market launch in India, and a pivotal US reimbursement decision on the horizon — yet its share price continues to drift lower. The medical-device giant recently completed a $550 million deal for Scientia Vascular, rolled out its PulseSelect ablation system in India, and awaits a September ruling from the Centers for Medicare & Medicaid Services that could open up transcatheter aortic valve replacement (TAVR) to asymptomatic patients. Despite this flurry of activity, the stock has struggled to find a foothold, trading at €68.34 and sitting just below its 50-day moving average of €68.64.
That technical barrier has turned from support into resistance, keeping the stock mired in a downtrend. So far this year, Medtronic has shed roughly 17% of its value, and the gap to its 200-day moving line stands at more than 13%. The shares came close to hitting a fresh low in early June, briefly dipping to €67.94 before staging a modest bounce. The message from the chart is clear: momentum remains to the downside, and the stock needs to reclaim the 50-day line to have any chance of a sustained recovery.
On the operational front, however, the company is pushing ahead aggressively. The launch of PulseSelect in India targets a population of roughly seven million people with atrial fibrillation. The system uses pulsed-field ablation, which relies on electrical fields rather than heat or cold to destroy faulty heart tissue, reducing damage to surrounding areas. That expansion follows a remarkable 78% surge in Medtronic’s cardiac ablation segment, underscoring the strength of its electrophysiology portfolio.
Should investors sell immediately? Or is it worth buying Medtronic?
Equally significant is the potential windfall from the CMS decision due in mid-September. If the agency approves Medicare coverage for TAVR in asymptomatic patients, the move would substantially widen the addressable patient pool — a direct shot in the arm for Medtronic’s valve business. The company has also applied for US clearance to expand the indications for its Hugo robotic surgery system, adding another arrow to its quiver. These initiatives come on the heels of what management describes as the strongest annual revenue growth in a decade.
The Scientia Vascular acquisition, closed in mid-June, bolsters Medtronic’s neurovascular lineup with technologies aimed at simplifying the treatment of complex conditions such as aneurysms. The $550 million upfront price tag, plus potential milestone payments, reflects the company’s strategy of shifting toward higher-margin clinical segments. But investors have so far shrugged off the deal, perhaps waiting for concrete evidence that these investments will translate into accelerated earnings growth.
Piper Sandler analysts have set a price target of $85 on the stock, calling the current valuation attractive with a forward price-to-earnings multiple of 14 — below the five-year average. Yet they caution that a more aggressive buying stance hinges on clearer proof of improving profit momentum. Medtronic’s depressed share price presents a paradox: the company is executing well operationally, but the market is demanding tangible bottom-line results before rewarding it.
For now, the stock remains caught between the gravitational pull of its technical weakness and the upward potential of its strategic moves. A clean break above the 50-day line combined with a favorable CMS ruling could provide the catalyst needed to change the narrative. Until then, Medtronic’s operational offensive may keep rolling, but the share price is likely to remain in a holding pattern.
Ad
Medtronic Stock: New Analysis - 18 June
Fresh Medtronic information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
